| abstract |
Methods for the inhibition of the various medical conditions associated with oestrogen deprivation syndrome, including osteoporosis and hyperlipidemia, using compounds of formula I, 1(a) and II are described. Specifically, ·the use of a compound of formula I (2-(4-hydroxyphenyl)-6-acetoxybenzo[b]thiophene) where; R and R1 could also be independently hydrogen, hydroxy, C1-C6 alkoxy, OCH2Ar, OCO(C1-C6 alkyl), OCOAr and Ar is phenyl or substituted phenyl; ·and a compound of formula II (raloxifene hydrochloride) where R2 and R3 could also be independently hydrogen, C1-C6 alkyl, CO(C1-C6 alkyl or COAr and R4 is pyrolidin-1-yl, piperidin-1-yl or hexamethyleneimin-1-yl; and where the nitrogen of the R4 group is optionally the N-oxide; ·and a compound of formula I(a) (2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thiophene) where R5 and R6 are independently hydroxy or methoxy; or a pharmaceutical salt or solvate thereof and pharmaceutical carriers, excipients or diluents. |